FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* JOHNSON KENNETH ERLAND						2. Issuer Name and Ticker or Trading Symbol Xeris Biopharma Holdings, Inc. [XERS]							5. Relationship of Reportir (Check all applicable) Director			ig Per	10% O	wner		
(Last) (First) (Middle) C/O XERIS BIOPHARMA HOLDINGS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/29/2022									Officer (give title below) See Remarks				specify		
1375 WEST FULTON STREET, SUITE 1300				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Lir	6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) CHICAGO IL 60607					Form filed by One Reporting Person Form filed by More than One Reporting Person															
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication																
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									nded to						
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Bene	eficia	ally	Own	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				and Securities Beneficial		ies cially Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) (D)	or	Price		Transa	ction(s) s and 4)			(111511.4)
Common Stock 0				01/29/2022(1)					F		7,497(2)	I)	\$2.11		440,443 ⁽³⁾			D	
Common Stock 01				01/31/20	01/31/2022(1)				F		2,307(4)	I)	\$2.11		438,136			D	
Common Stock				01/03/2023(1)				F		12,400(5)	I)	\$1.12		425,736			D		
Common	Stock			01/29/20)23(1)				F		11,029(6)	I)	\$1.2	26	41	4,707		D	
Common Stock 01/				01/31/20	01/31/2023(1)				F		3,393 ⁽⁷⁾	I)	\$1.24		411,314			D	
Common Stock 01/0				01/03/20	1/03/2024(1)				F		12,400(8)	I)	\$2.24		398,914			D	
Common Stock 01/2				01/29/20	1/29/2024(1)				F		10,747(9)	I)	\$2.66		388,167		D		
Common Stock 01/31/20				24(1)				F		15,131(10)) I)	\$2.46		373,036			D		
		Tal	ole II -								osed of, o					wned	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execut if any	3A. Deemed Execution Date,		ansaction ode (Instr.		vative virities vired r osed) r. 3, 4	_	Exerc	isable and	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		l nstr.	8. Pr	vative urity r. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form Direct or Inc (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Evolanation	n of Respons	.os.			Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or	ount nber res						
-	-	reported late due to a	dministra	ativa overcial	nt															

- 2. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022.
- 3. These shares include 1,080 shares that were purchased on June 30, 2024 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.
- 4. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
- 5. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023. 6. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
- 7. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
- 8. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
- 9. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
- 10. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31,

Remarks:

Senior Vice President, Global Development and Medical Affairs

/s/ Beth Hecht, as Attorney-in-

08/09/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in	n this form are not required to respond	unless the form displays a currently valid	OMB Number.